Evidence map›Paper›PMID 24691449›Full record

ArticlePloS one2014

Lack of Matrilin-2 favors liver tumor development via Erk1/2 and GSK-3β pathways in vivo.

Alexandra Fullár, Kornélia Baghy, Ferenc Deák, Bálint Péterfia, Yvonne Zsák, Péter Tátrai, Zsuzsa Schaff, József Dudás, Ibolya Kiss, Ilona Kovalszky

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Matrilin-2 is a novel prognostic marker in osteosarcoma.International journal of clinical and experimental pathology · 2019
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Alexandra Fullár1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Kornélia Baghy1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Ferenc DeákInstitute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary.
Bálint Péterfia1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Yvonne ZsákInstitute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary.
Péter Tátrai1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Zsuzsa Schaff2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
József DudásDepartment of Otorhinolaryngology, Medical University Innsbruck, Innsbruck, Austria.
Ibolya KissInstitute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary.
Ilona Kovalszky1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUInstitute of Biochemistry · HUHungarian Academy of Sciences · HUInnsbruck Medical University · AT

Funding

Austrian Science Fund FWF P 22287Austrian Science Fund FWF P 25869
6 · The paper itself

Abstract

Matrilin-2 (Matn2) is a multidomain adaptor protein which plays a role in the assembly of extracellular matrix (ECM). It is produced by oval cells during stem cell-driven liver regeneration. In our study, the impact of Matn2 on hepatocarcinogenesis was investigated in Matn2(-/-) mice comparing them with wild-type (WT) mice in a diethylnitrosamine (DEN) model. The liver tissue was analyzed macroscopically, histologically and immunohistochemically, at protein level by Proteome Profiler Arrays and Western blot analysis. Matn2(-/-) mice exhibited higher susceptibility to hepatocarcinogenesis compared to wild-type mice. In the liver of Matn2(-/-) mice, spontaneous microscopic tumor foci were detected without DEN treatment. After 15 μg/g body weight DEN treatment, the liver of Matn2(-/-) mice contained macroscopic tumors of both larger number and size than the WT liver. In contrast with the WT liver, spontaneous phosphorylation of EGFR, Erk1/2 GSK-3α/β and retinoblastoma protein (p-Rb), decrease in p21/CIP1 level, and increase in β-Catenin protein expression were detected in Matn2(-/-) livers. Focal Ki-67 positivity of these samples provided additional support to our presumption that the lack of Matn2 drives the liver into a pro-proliferatory state, making it prone to tumor development. This enhanced proliferative capacity was further increased in the tumor nodules of DEN-treated Matn2(-/-) livers. Our study suggests that Matn2 functions as a tumor suppressor in hepatocarcinogenesis, and in this process activation of EGFR together with that of Erk1/2, as well as inactivation of GSK-3β, play strategic roles.

Indexed as

Signal TransductionAnimalsCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaImmunohistochemistryLiver NeoplasmsMaleMatrilin ProteinsMiceMice, KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein TransportGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, mouseMatrilin ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3

Identifiers

PMID24691449
PMCPMC3972106
OpenAlexW2008049128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.